IXICO plc Issue of Equity (6328Z)
13 Gennaio 2020 - 2:29PM
UK Regulatory
TIDMIXI
RNS Number : 6328Z
IXICO plc
13 January 2020
13 January 2020
IXICO plc
("IXICO" or the "Company")
Issue of Equity
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, announces that it has made an application
to the London Stock Exchange for the admission to trading on AIM of
188,998 new ordinary shares of 1p each ("New Shares") to satisfy
the exercise of options.
The New Shares are expected to be admitted to trading on AIM on
15 January 2020.
Total voting rights
Application has been made for admission to trading on AIM of
188,998 New Shares. Admission of the New Shares on AIM is expected
to become effective at 8.00 a.m. on 15 January 2020, following
which there will be in total 47,091,292 ordinary shares in the
capital of the Company in issue, each carrying equal voting
rights.
This figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in,
IXICO under the FCA's Disclosure and Transparency Rules.
For further information please contact:
IXICO plc +44 (0) 20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0) 20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Optimum Strategic Communications +44 (0) 203 950 9144
Mary Clark / Supriya Mathur / Manuel Mateus
IXICO@optimumcomms.com
About IXICO
IXICO's purpose is to advance medicine and human health by
turning data into clinically meaningful information, providing
valuable new insights in neuroscience.
Our goal is to be a leading proponent in the use of Artificial
Intelligence (AI) in clinical development, to improve biopharma
R&D productivity through the adoption of breakthrough data
analytics in precision healthcare. Through the deployment of novel
AI algorithms, we analyse and interpret brain scans and digital
biosensor data to enable better trial design, patient selection and
ultimately clinical outcomes across all phases of clinical
evaluation. Our data analytics services are deployed on some of the
most important clinical trials in neuroscience, providing valuable
insights to disease progression and patient safety, enabling our
clients to make better informed decisions earlier in the clinical
development pathway.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEFLFFVLDIVLII
(END) Dow Jones Newswires
January 13, 2020 08:29 ET (13:29 GMT)
Grafico Azioni Ixico (LSE:IXI)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Ixico (LSE:IXI)
Storico
Da Apr 2023 a Apr 2024
